Parliament Workbench
Data: Motions & questions to 26 Nov 2026

Written Question · S7W-00814 · Session 7

In light of reports that mirvetuximab soravtansine will be made available to patients with ovarian cancer in England, whether it plans to f…

Answered Asked by Jackie Baillie Lab Lodged 4 Jun 2026

The question

To ask the Scottish Government, in light of reports that mirvetuximab soravtansine will be made available to patients with ovarian cancer in England, whether it plans to follow suit in Scotland.

The answer

Answered by Angela Constance on 16 Jun 2026 · 12 days after it was lodged, on time

The Scottish Medicines Consortium (SMC) has received a full submission from the marketing authorisation holder, AbbVie Ltd., for mirvetuximab soravtansine (elahere®) for the treatment of adult patients with ovarian cancer who have received one to three prior systemic treatment regimens and advice is expected to issue later this year.The medicine product page on the SMC’s website: mirvetuximab soravtansine (Elahere) will be updated once advice is published.

In the Official Report

No contribution in the Official Report cites S7W-00814 by reference.